Fate Therapeutics CEO granted options and RSUs

Q: Who is the insider involved in this Fate Therapeutics (FATE) Form 4 filing?

The filing reports transactions by Bahram Valamehr, who serves as President, CEO, and a director of Fate Therapeutics.

Q: What stock option grant did Fate Therapeutics (FATE) CEO Bahram Valamehr receive?

He was granted a stock option to purchase 1,300,000 shares of Fate Therapeutics common stock at an exercise price of $1.05 per share, with 1,300,000 options held directly after the transaction.

Q: How do the new stock options for the Fate Therapeutics (FATE) CEO vest?

The 1,300,000-share stock option vests in 36 equal monthly installments following January 1, 2026, so all shares are fully vested and exercisable on January 1, 2029, subject to his continued service.

Q: What restricted stock unit (RSU) award did the Fate Therapeutics (FATE) CEO receive?

He received 335,000 shares of common stock at $0.00, representing RSUs that vest 1/4 on each of January 8, 2027, 2028, 2029, and 2030, subject to continued service, with each RSU delivering one share upon settlement.

Q: Were the Fate Therapeutics (FATE) CEO equity awards reported as direct or indirect ownership?

Both the 335,000-share RSU-related common stock award and the 1,300,000-share stock option grant were reported as direct (D) ownership.

Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards. On January 15, 2026, he was granted 335,000 shares of common stock at a price of $0.00, representing restricted stock units that vest in four equal parts on January 8 of 2027, 2028, 2029 and 2030, contingent on continued service. On the same date, he was also granted a stock option for 1,300,000 shares of common stock at an exercise price of $1.05 per share, vesting in 36 equal monthly installments after January 1, 2026, and becoming fully vested on January 1, 2029, subject to continued service. Following the stock award, he beneficially owned 664,708 shares of common stock directly, and held 1,300,000 stock options directly.

Insider Trade Summary

Grant/Award: 1,635,000 shares

Grant/Award 2 txns

Insider Valamehr Bahram

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,300,000	$0.00	$0.00
Grant/Award	Common Stock	335,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,300,000 contracts (Direct); Common Stock — 664,708 shares (Direct)

Footnotes (2)

F1. Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
F2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

FAQ

Who is the insider involved in this Fate Therapeutics (FATE) Form 4 filing?

The filing reports transactions by Bahram Valamehr, who serves as President, CEO, and a director of Fate Therapeutics.

What stock option grant did Fate Therapeutics (FATE) CEO Bahram Valamehr receive?

He was granted a stock option to purchase 1,300,000 shares of Fate Therapeutics common stock at an exercise price of $1.05 per share, with 1,300,000 options held directly after the transaction.

How do the new stock options for the Fate Therapeutics (FATE) CEO vest?

The 1,300,000-share stock option vests in 36 equal monthly installments following January 1, 2026, so all shares are fully vested and exercisable on January 1, 2029, subject to his continued service.

What restricted stock unit (RSU) award did the Fate Therapeutics (FATE) CEO receive?

He received 335,000 shares of common stock at $0.00, representing RSUs that vest 1/4 on each of January 8, 2027, 2028, 2029, and 2030, subject to continued service, with each RSU delivering one share upon settlement.

How many Fate Therapeutics (FATE) shares does the CEO own after this Form 4 transaction?

After the reported RSU-related award, Bahram Valamehr beneficially owned 664,708 shares of common stock directly, in addition to 1,300,000 stock options held directly.

Were the Fate Therapeutics (FATE) CEO equity awards reported as direct or indirect ownership?

Both the 335,000-share RSU-related common stock award and the 1,300,000-share stock option grant were reported as direct (D) ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/16/2026 - 04:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valamehr Bahram

(Last)

(First)

(Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO

92131

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/15/2026		A⁽¹⁾		335,000	A	$0.00	664,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.05	01/15/2026		A		1,300,000		⁽²⁾	01/14/2036	Common Stock	1,300,000	$0.00	1,300,000	D

Explanation of Responses:

1. Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

	/s/ Cindy Tahl, as Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR